Mode
Text Size
Log in / Sign up

Clinical Trial Search

Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.

Phase
Intervention
Population
Results posted

65,437 trials

Phase 3 N=94 Treatment for Endogenous Cushing's Syndrome

Endogenous Cushing's Syndrome
Primary: Normalization in Urinary Free Cortisol in Patients With Endogenous Cushing's Syndrome. — .30 proportion of subjects meeting endpoint — p=0.0154
Cortendo AB Results Apr 2021 17.0% serious AE View details

Phase 1 N=32 Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

Diffuse Large B Cell Lymphoma · Primary Mediastinal Lymphoma · Mantle Cell Lymphoma
Primary: Part A: Effect of CYP3A Inhibition by Fluconazole on the PK of Tazemetostat (AUC0-t, AUC0-8) — 1340; 4100 h*ng/mL
Epizyme, Inc. Results Apr 2021 31.3% serious AE View details

Phase 2 N=84 Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Seasonal Influenza · Influenza · Influenza Due to Unspecified Influenza Virus
Primary: Cell Mediated Immune (CMI) Responses After In-vitro Restimulation Of Peripheral Blood Mononuclear Cells (PBMC) Following Vaccination. — 631; 655; 1560; 1137 Cells per…
Novartis Vaccines Results Apr 2021 2.4% serious AE View details